INMB · Inmune Bio, Inc. · Executive Compensation
$1.93
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$56.34M
Shares
27.75M
Volume · Oct 2
290.24K
Avg daily vol (3M)
455.31K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | M.D., former CEO, President and CMO | $2,849,504 |
| David J. Moss | CEO and President | $1,845,179 |
| Mark Lowdell | CSO | $1,452,236 |
| Cory Ellspermann | CFO | $619,227 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $3,008,174 |
| David J. Moss | CFO | $2,722,003 |
| Mark Lowdell | CSO | $1,792,412 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,694,818 |
| David J. Moss | CFO | $1,589,218 |
| Mark Lowdell | CSO | $150,237 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $1,444,509 |
| David J. Moss | CFO | $1,298,169 |
| Mark Lowdell | CSO | $904,599 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Raymond J. Tesi | CEO/President/CMO | $2,702,228 |
| David J. Moss | CFO | $2,631,228 |
| Mark Lowdell | CSO | $149,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David J. Moss | CFO | $300,000 |
| Raymond J. Tesi | CEO/President/CMO | $300,000 |
| Mark Lowdell | CSO | $138,204 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James Sapirstein | members of the Nominating and Corporate Governance Committee of the Board | Appointed | 2026-09-14 |
| James Sapirstein | directors of the Company | Appointed | 2026-09-14 |
| R. Duane Clark II | members of the Nominating and Corporate Governance Committee of the Board | Appointed | 2026-09-14 |
| R. Duane Clark II | directors of the Company | Appointed | 2026-09-14 |
| Scott Juda, JD | Director | Appointed | 2026-06-17 |
| Marcia Allen | Director | Appointed | 2026-06-17 |
| Tim Schroeder | Director | Appointed | 2026-06-17 |
| J. Kelly Ganjei | Director | Appointed | 2026-06-17 |
| David Moss | Director | Appointed | 2026-06-17 |
| Cory Ellspermann | Chief Financial Officer | Appointed | 2025-11-28 |
| Marcia Allen | Director | Appointed | 2025-06-10 |
| Tim Schroeder | Director | Appointed | 2025-06-10 |
| Scott Juda, JD | Director | Appointed | 2025-06-10 |
| J. Kelly Ganjei | Director | Appointed | 2025-06-10 |
| Raymond J. Tesi, MD | Director | Appointed | 2025-06-10 |
| Edgardo Baracchini | board of directors | Resigned | 2024-07-05 |
| Marcia Allen | Director | Appointed | 2023-06-01 |
| Edgardo Baracchini, PhD | Director | Appointed | 2023-06-01 |
| Scott Juda, JD | Director | Appointed | 2023-06-01 |
| Tim Schroeder | Director | Appointed | 2023-06-01 |
| J. Kelly Ganjei | Director | Appointed | 2023-06-01 |
| Raymond J. Tesi, MD | Director | Appointed | 2023-06-01 |